Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Sign Up to like & getrecommendations! Published in 2019 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2019.103254
Abstract: The free fatty acid receptor 1 (FFA1) and peroxisome proliferator-activated receptor δ (PPARδ) were considered as potential anti-diabetic targets, and the dual FFA1/PPARδ agonists might provide synergistic effect in insulin secretion and sensibility. Herein, we… read more here.
Keywords: ppar; ppar agonists; ffa1; potential anti ... See more keywords
The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Autoimmunity"
DOI: 10.1016/j.jaut.2020.102510
Abstract: Abstract Autoimmune diseases are common diseases of the immune system that are characterized by the loss of self-tolerance and the production of autoantibodies; the breakdown of immune tolerance and the prolonged inflammatory reaction are undisputedly… read more here.
Keywords: ppar agonists; ppar ppar; roles ppar; autoimmune diseases ... See more keywords
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2020.04.025
Abstract: BACKGROUND AND AIMS Peroxisome proliferator-activated receptors (PPARs) are essential regulators of whole-body metabolism, but also modulate inflammation in immune cells, notably macrophages. We compared selective PPAR agonists with the pan-PPAR agonist lanifibranor as therapeutic agents… read more here.
Keywords: ppar; ppar agonists; hepatic macrophages; pan ppar ... See more keywords
Synthesis of a unique dimethyl thiazoline containing intermediate of novel peroxisome proliferator-activated receptors(PPAR)δ agonists
Sign Up to like & getrecommendations! Published in 2018 at "Tetrahedron Letters"
DOI: 10.1016/j.tetlet.2018.10.051
Abstract: Abstract Peroxisome proliferator-activated receptor delta (PPARδ) is considered as a promising biological target for the development of new drugs to treat metabolic syndrome including hyperlipidemia. In this study, a simple and efficient method for the… read more here.
Keywords: peroxisome proliferator; ppar agonists; dimethyl; proliferator activated ... See more keywords
Novel PPAR-γ agonists as potential neuroprotective agents against Alzheimer's disease: rational design, synthesis, in silico evaluation, PPAR-γ binding assay and transactivation and expression studies
Sign Up to like & getrecommendations! Published in 2024 at "RSC Advances"
DOI: 10.1039/d4ra06330a
Abstract: Alzheimer's disease (AD) is a neurological disorder. It is caused by accumulation of amyloid beta (Aβ) plaques and tau tangles, which gradually leads to cognitive decline and memory loss. Peroxisome proliferator-activated receptor gamma (PPAR-γ), a… read more here.
Keywords: alzheimer disease; ppar agonists; ppar; binding assay ... See more keywords
PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Medicine"
DOI: 10.1080/07853890.2025.2497112
Abstract: Abstract Background and aim Lipid accumulation in hepatocytes is reduced by the activation of the peroxisome proliferator-activated receptor (PPAR) α, which is associated with increased lysosomal acid lipase (LAL) activity, transcription factor EB (TFEB) expression,… read more here.
Keywords: lipid accumulation; ppar agonists; accumulation; accumulation hepatocytes ... See more keywords
PPARγ agonists delay age‐associated metabolic disease and extend longevity
Sign Up to like & getrecommendations! Published in 2020 at "Aging Cell"
DOI: 10.1111/acel.13267
Abstract: Aging leads to a number of disorders caused by cellular senescence, tissue damage, and organ dysfunction. It has been reported that anti‐inflammatory and insulin‐sensitizing compounds delay, or reverse, the aging process and prevent metabolic disorders,… read more here.
Keywords: ppar agonists; longevity; age; disease ... See more keywords
Is pulmonary vascular disease reversible with PPAR ɣ agonists?
Sign Up to like & getrecommendations! Published in 2018 at "Microcirculation"
DOI: 10.1111/micc.12444
Abstract: Severe angio‐obliterative PAH remains a disease characterized by great morbidity and shortened survival. Unfortunately, the only currently available treatments for angio‐obliterative changes are palliative in the form of pulmonary vasodilators evolving from the phosphodiesterase inhibitor… read more here.
Keywords: ppar; ppar agonists; angio obliterative; vascular disease ... See more keywords
Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2025 at "BMC Gastroenterology"
DOI: 10.1186/s12876-025-03821-2
Abstract: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease. Some patients with PBC do not adequately respond to Ursodeoxycholic acid (UDCA) as a first-line treatment, putting them at an increased risk of disease… read more here.
Keywords: ppar agonists; ppar; safety ppar; primary biliary ... See more keywords
Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
Sign Up to like & getrecommendations! Published in 2017 at "Current pharmaceutical design"
DOI: 10.2174/1381612823666161118145850
Abstract: Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three… read more here.
Keywords: ppar; peroxisome proliferator; ppar agonists; treatment ... See more keywords
Novel Cinnamic Acid Derivatives as Potential PPARδ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies.
Sign Up to like & getrecommendations! Published in 2019 at "Current drug discovery technologies"
DOI: 10.2174/1570163816666190314124543
Abstract: Peroxisome proliferator-activated receptor (PPAR) δ is expressed universally in the entire tissues, particularly in those concerned with the lipid metabolism. PPAR δ stimulation alters body's energy fuel preference to fat from glucose and shows up… read more here.
Keywords: ppar; ppar agonists; novel cinnamic; cinnamic acid ... See more keywords